Okubo et al. reported lower LAT1 expression in low-grade compared to high-grade gliomas and an increasing level of LAT1 immunostaining with higher glioma grades [31], which may also explain the generally low staining intensity in our patients. This evidence concerns the gene SLC7A5 and central nervous system cancer.